动物造模,高尿酸血症性肾损害小鼠模型 z-bio 2021-10-22 315

　　Objective: To establish a reasonable and stable mouse model of hyperuricemia nephropathy, and provide a pathological model for screening and researching therapeutic agents for hyperuricemia nephropathy?

　　Method: Potassium oxalate? Hypoxanthine? Adenine? Use ethambutol and yeast cream 5 modeling agent alone, combine with two reagents, or combine with three reagents to observe different modeling times. Modeling dosage and modeling method are used to establish serum in mouse hyperuricemia nephropathy model. Uric acid? Urinary nitrogen and creatinine levels? Changes in the activities of liver xanthine oxidase (XOD) and adenosine deaminase (ADA)? What are the pathology and weight changes of each group of kidneys?

　　Results: Compared with the normal group, the serum uric acid level and urea nitrogen of the hypoxanthine and potassium oxalate single model mice were significantly increased (P\u003c0.01). The kidney tubules were cast as kidneys. Salt was found in renal medulla crystals; when combined with hypoxanthine, etabaol and potassium oxalate, the serum uric acid level and urea nitrogen of mice in the 7d group were significantly increased (P\u003c0.01 ), XOD liver activity is significantly reduced (P\u003c0.05), and the kidney becomes closer to eosinophil insoluble protein. Complicated tubules; compared with the normal group, the serum uric acid, urea nitrogen and creatinine levels of mice in the yeast extract and potassium oxalate 14d group and yeast extract, adenine and potassium oxalate 14d group were significantly increased (P\ u003c 0.01) In the combination group of yeast cream and potassium oxalate, renal tubular epithelial cells are shed, and eosinophilic insoluble proteins are found in the proximal gyrus of the kidney, yeast cream, and adenine. Potassium oxalate has salt crystals in the kidney The weight gain of mice in the combined treatment of medullary bulbar yeast cream and potassium oxalate was faster than that in the combined treatment of yeast cream, adenine and potassium oxalate, and the difference between the two groups was significant.

　　Conclusion: Compared with other modeling methods, the hyperuricemia nephropathy mouse model established by the combination of yeast extract and potassium oxazine is more stable and has a significant effect on the body weight of the mice. At the same time, because the modeling method is more in line with clinical characteristics, is it more appropriate to use yeast extract and potassium oxazine to establish a 14-day mouse model of hyperuricemia nephropathy?